Iomeron (Iomeprol)

Iomeprol contains multiple iodine atoms that absorb X‑ray photons more effectively than surrounding tissues. When injected, it creates a temporary high‑contrast environment in the targeted compartment, allowing X‑ray‑based imaging systems to differentiate structures with greater clarity. Its low‑osmolality formulation reduces discomfort while maintaining strong radiodensity.

The dose of Iomeron is determined by the prescribing physician based on the specific imaging study, patient weight, renal function and the route of administration. Healthcare professionals calculate the appropriate volume to achieve optimal contrast enhancement while considering safety guidelines.

The safety of Iomeron during pregnancy and lactation has not been definitively established. It is generally avoided unless the diagnostic benefit outweighs potential risks. Clinicians should discuss possible effects with the patient and consider alternative imaging strategies when feasible.

To order Iomeron, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Iomeron (iomeprol) is a non‑ionic, low‑osmolality agent similar to other modern iodinated contrasts such as iohexol or iopamidol. Compared with older high‑osmolality agents, it typically offers reduced injection discomfort and a lower incidence of adverse reactions while delivering comparable image quality. Choice among agents often depends on institutional preference, specific procedural requirements and patient risk factors.

Iomeron should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the solution from direct light, moisture and extreme temperature fluctuations. Do not freeze the product, and inspect the vial for particulate matter before use.

Iomeron is supplied as a sterile aqueous solution for injection. It can be administered intraarterially for vascular angiography, intraarticularly for joint imaging, or intrathecally for neuroradiologic studies. The injection is performed by qualified healthcare professionals using aseptic technique and appropriate delivery devices.

The most serious risks include severe allergic reactions such as anaphylaxis, contrast‑induced nephropathy leading to acute kidney injury, and cardiovascular events like profound hypotension or cardiac arrest. Prompt recognition and emergency management are essential if any of these reactions occur during or after administration.

Iomeron should be avoided in patients with a known hypersensitivity to iodinated contrast media, severe renal impairment (eGFR < 30 mL/min/1.73 m²) unless benefits outweigh risks, uncontrolled hyperthyroidism, and in pregnant or breastfeeding women unless the diagnostic information is critical and no alternatives exist.